410 related articles for article (PubMed ID: 31990313)
1. Dapagliflozin Cut Risk of Worsening Heart Failure.
Slomski A
JAMA; 2020 Jan; 323(4):301. PubMed ID: 31990313
[No Abstract] [Full Text] [Related]
2. Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes.
Petrie MC; Verma S; Docherty KF; Inzucchi SE; Anand I; Belohlávek J; Böhm M; Chiang CE; Chopra VK; de Boer RA; Desai AS; Diez M; Drozdz J; Dukát A; Ge J; Howlett J; Katova T; Kitakaze M; Ljungman CEA; Merkely B; Nicolau JC; O'Meara E; Vinh PN; Schou M; Tereshchenko S; Køber L; Kosiborod MN; Langkilde AM; Martinez FA; Ponikowski P; Sabatine MS; Sjöstrand M; Solomon SD; Johanson P; Greasley PJ; Boulton D; Bengtsson O; Jhund PS; McMurray JJV
JAMA; 2020 Apr; 323(14):1353-1368. PubMed ID: 32219386
[TBL] [Abstract][Full Text] [Related]
3. Dapagliflozin in patients with heart failure and reduced ejection fraction.
Colombo G; Casella R; Cazzaniga A; Casiraghi C;
Intern Emerg Med; 2020 Apr; 15(3):515-517. PubMed ID: 32124206
[No Abstract] [Full Text] [Related]
4. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
McMurray JJV; Solomon SD; Inzucchi SE; Køber L; Kosiborod MN; Martinez FA; Ponikowski P; Sabatine MS; Anand IS; Bělohlávek J; Böhm M; Chiang CE; Chopra VK; de Boer RA; Desai AS; Diez M; Drozdz J; Dukát A; Ge J; Howlett JG; Katova T; Kitakaze M; Ljungman CEA; Merkely B; Nicolau JC; O'Meara E; Petrie MC; Vinh PN; Schou M; Tereshchenko S; Verma S; Held C; DeMets DL; Docherty KF; Jhund PS; Bengtsson O; Sjöstrand M; Langkilde AM;
N Engl J Med; 2019 Nov; 381(21):1995-2008. PubMed ID: 31535829
[TBL] [Abstract][Full Text] [Related]
5. Dapagliflozin (Farxiga) - a new indication for heart failure.
Med Lett Drugs Ther; 2020 Jun; 62(1601):102-103. PubMed ID: 32724023
[No Abstract] [Full Text] [Related]
6. SGLT2 inhibitors in people with and without T2DM.
Khunti K
Nat Rev Endocrinol; 2021 Feb; 17(2):75-76. PubMed ID: 33293703
[No Abstract] [Full Text] [Related]
7. Introduction.
Chilton RJ
Am J Cardiol; 2017 Jul; 120(1S):S1-S3. PubMed ID: 28606339
[No Abstract] [Full Text] [Related]
8. Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.
Kato ET; Silverman MG; Mosenzon O; Zelniker TA; Cahn A; Furtado RHM; Kuder J; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Bonaca MP; Ruff CT; Desai AS; Goto S; Johansson PA; Gause-Nilsson I; Johanson P; Langkilde AM; Raz I; Sabatine MS; Wiviott SD
Circulation; 2019 May; 139(22):2528-2536. PubMed ID: 30882238
[TBL] [Abstract][Full Text] [Related]
9. NICE guidance on dapagliflozin for chronic heart failure with reduced ejection fraction.
Adler AI; Douch E; Dunning L; Elliott N
Lancet Diabetes Endocrinol; 2021 May; 9(5):261-263. PubMed ID: 33713596
[No Abstract] [Full Text] [Related]
10. The DAPA-HF Trial: A Momentous Victory in the War against Heart Failure.
Bhatt DL; Verma S; Braunwald E
Cell Metab; 2019 Nov; 30(5):847-849. PubMed ID: 31693879
[TBL] [Abstract][Full Text] [Related]
11. Reconceptualization of the Molecular Mechanism by Which Sodium-Glucose Cotransporter 2 Inhibitors Reduce the Risk of Heart Failure Events.
Packer M
Circulation; 2019 Aug; 140(6):443-445. PubMed ID: 31381418
[No Abstract] [Full Text] [Related]
12. Positive effect of dapagliflozin on left ventricular longitudinal function for type 2 diabetic mellitus patients with chronic heart failure.
Tanaka H; Soga F; Tatsumi K; Mochizuki Y; Sano H; Toki H; Matsumoto K; Shite J; Takaoka H; Doi T; Hirata KI
Cardiovasc Diabetol; 2020 Jan; 19(1):6. PubMed ID: 31910853
[TBL] [Abstract][Full Text] [Related]
13. [Not Available].
Lanthier L; Dussault C; Huard G; Plourde MÉ; Cauchon M
Rev Med Interne; 2020 Feb; 41(2):143-144. PubMed ID: 31928796
[No Abstract] [Full Text] [Related]
14. Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA-HF.
Docherty KF; Jhund PS; Anand I; Bengtsson O; Böhm M; de Boer RA; DeMets DL; Desai AS; Drozdz J; Howlett J; Inzucchi SE; Johanson P; Katova T; Køber L; Kosiborod MN; Langkilde AM; Lindholm D; Martinez FA; Merkely B; Nicolau JC; O'Meara E; Ponikowski P; Sabatine MS; Sjöstrand M; Solomon SD; Tereshchenko S; Verma S; McMurray JJV
Circulation; 2020 Oct; 142(17):1623-1632. PubMed ID: 32883108
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of dapagliflozin in acute heart failure: Rationale and design of the DICTATE-AHF trial.
Cox ZL; Collins SP; Aaron M; Hernandez GA; Iii ATM; Davidson BT; Fowler M; Lindsell CJ; Jr FEH; Jenkins CA; Kampe C; Miller KF; Stubblefield WB; Lindenfeld J
Am Heart J; 2021 Feb; 232():116-124. PubMed ID: 33144086
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of Dapagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction.
Parizo JT; Goldhaber-Fiebert JD; Salomon JA; Khush KK; Spertus JA; Heidenreich PA; Sandhu AT
JAMA Cardiol; 2021 Aug; 6(8):926-935. PubMed ID: 34037681
[TBL] [Abstract][Full Text] [Related]
17. FDA Expands Empagliflozin Heart Failure Indication.
Larkin HD
JAMA; 2022 Apr; 327(13):1219. PubMed ID: 35380600
[No Abstract] [Full Text] [Related]
18. Dapagliflozin Safe and Effective for Heart Failure With Frailty.
Slomski A
JAMA; 2022 May; 327(20):1950. PubMed ID: 35608583
[No Abstract] [Full Text] [Related]
19. Antidiabetic Drug Approved to Reduce Risk of Kidney Disease.
Aschenbrenner DS
Am J Nurs; 2021 Sep; 121(9):25. PubMed ID: 34438427
[TBL] [Abstract][Full Text] [Related]
20. Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction.
Furtado RHM; Bonaca MP; Raz I; Zelniker TA; Mosenzon O; Cahn A; Kuder J; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Ruff CT; Nicolau JC; Gause-Nilsson IAM; Fredriksson M; Langkilde AM; Sabatine MS; Wiviott SD
Circulation; 2019 May; 139(22):2516-2527. PubMed ID: 30882239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]